HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $993,391 | +10.3% | 26,005 | +4.2% | 0.18% | +12.2% |
| Q2 2023 | $900,271 | -4.6% | 24,959 | +1.0% | 0.16% | -7.7% |
| Q1 2023 | $943,828 | -47.3% | 24,714 | -21.5% | 0.17% | -47.7% |
| Q4 2022 | $1,792,066 | +37.7% | 31,495 | -4.3% | 0.32% | +24.7% |
| Q3 2022 | $1,301,000 | +4.5% | 32,913 | +16.3% | 0.26% | +8.8% |
| Q2 2022 | $1,245,000 | -17.4% | 28,293 | -25.2% | 0.24% | -1.7% |
| Q1 2022 | $1,508,000 | +4.6% | 37,820 | +5.5% | 0.24% | +13.6% |
| Q4 2021 | $1,442,000 | -24.0% | 35,850 | -23.2% | 0.21% | -26.6% |
| Q3 2021 | $1,898,000 | -9.3% | 46,669 | +1.3% | 0.29% | -5.8% |
| Q2 2021 | $2,093,000 | +7.8% | 46,086 | -1.0% | 0.31% | +1.3% |
| Q1 2021 | $1,942,000 | -3.7% | 46,574 | -1.4% | 0.30% | -8.7% |
| Q4 2020 | $2,017,000 | +64.1% | 47,226 | +1.0% | 0.33% | +47.3% |
| Q3 2020 | $1,229,000 | -2.6% | 46,750 | -0.7% | 0.23% | -5.0% |
| Q2 2020 | $1,262,000 | +34.7% | 47,074 | -9.6% | 0.24% | +15.0% |
| Q1 2020 | $937,000 | +2.0% | 52,073 | +0.5% | 0.21% | +31.0% |
| Q4 2019 | $919,000 | +27.8% | 51,832 | +11.8% | 0.16% | +102.6% |
| Q3 2019 | $719,000 | -9.4% | 46,353 | +0.2% | 0.08% | -4.9% |
| Q2 2019 | $794,000 | -4.8% | 46,243 | -10.8% | 0.08% | -6.8% |
| Q1 2019 | $834,000 | +10.0% | 51,827 | 0.0% | 0.09% | -2.2% |
| Q4 2018 | $758,000 | -4.9% | 51,827 | +18.1% | 0.09% | +12.5% |
| Q3 2018 | $797,000 | +25.7% | 43,876 | +16.8% | 0.08% | +21.2% |
| Q2 2018 | $634,000 | -17.1% | 37,552 | -3.8% | 0.07% | -16.5% |
| Q1 2018 | $765,000 | -2.2% | 39,040 | +1.2% | 0.08% | +2.6% |
| Q4 2017 | $782,000 | +50.4% | 38,588 | +28.9% | 0.08% | +51.0% |
| Q3 2017 | $520,000 | +36.5% | 29,945 | +0.9% | 0.05% | +27.5% |
| Q2 2017 | $381,000 | -4.5% | 29,687 | -3.6% | 0.04% | -4.8% |
| Q1 2017 | $399,000 | -32.8% | 30,786 | -48.8% | 0.04% | -33.3% |
| Q4 2016 | $594,000 | – | 60,119 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |